WallStreetZenWallStreetZen

NASDAQ: CASI
Casi Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CASI

Based on 1 analyst offering 12 month price targets for Casi Pharmaceuticals Inc

Min Forecast
$4.00+292.16%
Avg Forecast
$4.00+292.16%
Max Forecast
$4.00+292.16%

Should I buy or sell CASI stock?

Based on 1 analyst offering ratings for Casi Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CASI stock forecasts and price targets.

CASI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-03

1 of 1

Forecast return on equity

Is CASI forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is CASI forecast to generate an efficient return on assets?

Company
N/A
Industry
93.69%

CASI earnings per share forecast

What is CASI's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$2.36
Avg 2 year Forecast
-$1.48
Avg 3 year Forecast
-$1.44

CASI revenue forecast

What is CASI's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$10.6M-60.43%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%

CASI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CASI$1.02$4.00+292.16%Buy
ALLR$1.33$9.25+595.49%Buy
GDTC$1.84N/AN/A
MRKR$1.24N/AN/A
TRAW$2.70N/AN/A
View Top Biotech Stocks

Casi Pharmaceuticals Stock Forecast FAQ

Is Casi Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CASI) stock is to Buy CASI stock.

Out of 1 analyst, 0 (0%) are recommending CASI as a Strong Buy, 1 (100%) are recommending CASI as a Buy, 0 (0%) are recommending CASI as a Hold, 0 (0%) are recommending CASI as a Sell, and 0 (0%) are recommending CASI as a Strong Sell.

If you're new to stock investing, here's how to buy Casi Pharmaceuticals stock.

What is CASI's earnings growth forecast for 2025-2027?

(NASDAQ: CASI) Casi Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.81%.

Casi Pharmaceuticals's earnings in 2025 is -$49,378,000.On average, 3 Wall Street analysts forecast CASI's earnings for 2025 to be -$48,415,841, with the lowest CASI earnings forecast at -$46,517,180, and the highest CASI earnings forecast at -$49,839,836. On average, 3 Wall Street analysts forecast CASI's earnings for 2026 to be -$30,390,896, with the lowest CASI earnings forecast at -$29,199,096, and the highest CASI earnings forecast at -$31,284,746.

In 2027, CASI is forecast to generate -$29,552,526 in earnings, with the lowest earnings forecast at -$28,393,604 and the highest earnings forecast at -$30,421,718.

What is CASI's revenue growth forecast for 2025-2027?

(NASDAQ: CASI) Casi Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.

Casi Pharmaceuticals's revenue in 2025 is $26,846,000.On average, 3 Wall Street analysts forecast CASI's revenue for 2025 to be $218,284,304, with the lowest CASI revenue forecast at $209,736,223, and the highest CASI revenue forecast at $224,715,914. On average, 3 Wall Street analysts forecast CASI's revenue for 2026 to be $0, with the lowest CASI revenue forecast at $0, and the highest CASI revenue forecast at $0.

In 2027, CASI is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is CASI's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CASI) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 93.69%.

What is CASI's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CASI price target, the average CASI price target is $4.00, with the highest CASI stock price forecast at $4.00 and the lowest CASI stock price forecast at $4.00.

The Wall Street analyst predicted that Casi Pharmaceuticals's share price could reach $4.00 by Sep 3, 2026. The average Casi Pharmaceuticals stock price prediction forecasts a potential upside of 292.16% from the current CASI share price of $1.02.

What is CASI's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CASI) Casi Pharmaceuticals's current Earnings Per Share (EPS) is -$3.01. On average, analysts forecast that CASI's EPS will be -$2.36 for 2025, with the lowest EPS forecast at -$2.26, and the highest EPS forecast at -$2.43. On average, analysts forecast that CASI's EPS will be -$1.48 for 2026, with the lowest EPS forecast at -$1.42, and the highest EPS forecast at -$1.52. In 2027, CASI's EPS is forecast to hit -$1.44 (min: -$1.38, max: -$1.48).

What is CASI's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CASI) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.